Cargando…

Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology

The early detection of infectious diseases and microorganisms is critical for effective disease treatment, control, and prevention. Currently, nucleic acid testing and antigen–antibody serum reaction are the two methods most commonly used for the detection of infectious diseases. The former is highl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shiu-Jau, Rai, Chung-I, Wang, Shao-Cheng, Chen, Yuan-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340307/
https://www.ncbi.nlm.nih.gov/pubmed/37443646
http://dx.doi.org/10.3390/diagnostics13132255
_version_ 1785072047427158016
author Chen, Shiu-Jau
Rai, Chung-I
Wang, Shao-Cheng
Chen, Yuan-Chuan
author_facet Chen, Shiu-Jau
Rai, Chung-I
Wang, Shao-Cheng
Chen, Yuan-Chuan
author_sort Chen, Shiu-Jau
collection PubMed
description The early detection of infectious diseases and microorganisms is critical for effective disease treatment, control, and prevention. Currently, nucleic acid testing and antigen–antibody serum reaction are the two methods most commonly used for the detection of infectious diseases. The former is highly accurate, specific, and sensitive, but it is time-consuming, expensive, and has special technician and instrument requirements. The latter is rapid and economical, but it may not be accurate and sensitive enough. Therefore, it is necessary to develop a quick and on-site diagnostic test for point-of-care testing (POCT) to enable the clinical detection of infectious diseases that is accurate, sensitive, convenient, cheap, and portable. Here, CRISPR/Cas-based detection methods are detailed and discussed in depth. The powerful capacity of these methods will facilitate the development of diagnostic tools for POCT, though they still have some limitations. This review explores and highlights POCT based on the class 2 CRISPR/Cas assay, such as Cas12 and Cas13 proteins, for the detection of infectious diseases. We also provide an outlook on perspectives, multi-application scenarios, clinical applications, and limitations for POCT based on class 2 CRISPR/Cas technology.
format Online
Article
Text
id pubmed-10340307
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103403072023-07-14 Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology Chen, Shiu-Jau Rai, Chung-I Wang, Shao-Cheng Chen, Yuan-Chuan Diagnostics (Basel) Review The early detection of infectious diseases and microorganisms is critical for effective disease treatment, control, and prevention. Currently, nucleic acid testing and antigen–antibody serum reaction are the two methods most commonly used for the detection of infectious diseases. The former is highly accurate, specific, and sensitive, but it is time-consuming, expensive, and has special technician and instrument requirements. The latter is rapid and economical, but it may not be accurate and sensitive enough. Therefore, it is necessary to develop a quick and on-site diagnostic test for point-of-care testing (POCT) to enable the clinical detection of infectious diseases that is accurate, sensitive, convenient, cheap, and portable. Here, CRISPR/Cas-based detection methods are detailed and discussed in depth. The powerful capacity of these methods will facilitate the development of diagnostic tools for POCT, though they still have some limitations. This review explores and highlights POCT based on the class 2 CRISPR/Cas assay, such as Cas12 and Cas13 proteins, for the detection of infectious diseases. We also provide an outlook on perspectives, multi-application scenarios, clinical applications, and limitations for POCT based on class 2 CRISPR/Cas technology. MDPI 2023-07-03 /pmc/articles/PMC10340307/ /pubmed/37443646 http://dx.doi.org/10.3390/diagnostics13132255 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chen, Shiu-Jau
Rai, Chung-I
Wang, Shao-Cheng
Chen, Yuan-Chuan
Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology
title Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology
title_full Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology
title_fullStr Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology
title_full_unstemmed Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology
title_short Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology
title_sort point-of-care testing for infectious diseases based on class 2 crispr/cas technology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340307/
https://www.ncbi.nlm.nih.gov/pubmed/37443646
http://dx.doi.org/10.3390/diagnostics13132255
work_keys_str_mv AT chenshiujau pointofcaretestingforinfectiousdiseasesbasedonclass2crisprcastechnology
AT raichungi pointofcaretestingforinfectiousdiseasesbasedonclass2crisprcastechnology
AT wangshaocheng pointofcaretestingforinfectiousdiseasesbasedonclass2crisprcastechnology
AT chenyuanchuan pointofcaretestingforinfectiousdiseasesbasedonclass2crisprcastechnology